126 related articles for article (PubMed ID: 19776486)
41. HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.
Palmer TJ; McFadden M; Pollock KG; Kavanagh K; Cuschieri K; Cruickshank M; Cotton S; Nicoll S; Robertson C
Br J Cancer; 2016 Mar; 114(5):582-9. PubMed ID: 26931370
[TBL] [Abstract][Full Text] [Related]
42. Screening of cervical neoplasia in HIV-infected women in India.
Joshi S; Sankaranarayanan R; Muwonge R; Kulkarni V; Somanathan T; Divate U
AIDS; 2013 Feb; 27(4):607-15. PubMed ID: 23079814
[TBL] [Abstract][Full Text] [Related]
43. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
44. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
[TBL] [Abstract][Full Text] [Related]
45. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
Bokan T; Ivanus U; Jerman T; Takac I; Arko D
Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
[TBL] [Abstract][Full Text] [Related]
46. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
47. Detection of high-grade cervical disease among women referred directly to colposcopy after a positive HPV screening test varies with age and cytology findings.
Farnsworth A; Roberts JM; Garland SM; Crescini J; Kaldor JM; Machalek DA
Int J Cancer; 2020 Dec; 147(11):3068-3074. PubMed ID: 32484236
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
49. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma.
Wentzensen N; Schiffman M; Dunn ST; Zuna RE; Walker J; Allen RA; Zhang R; Sherman ME; Wacholder S; Jeronimo J; Gold MA; Wang SS
Int J Cancer; 2009 Feb; 124(4):964-9. PubMed ID: 19030188
[TBL] [Abstract][Full Text] [Related]
50. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial.
Verhoef VM; Bosgraaf RP; van Kemenade FJ; Rozendaal L; Heideman DA; Hesselink AT; Bekkers RL; Steenbergen RD; Massuger LF; Melchers WJ; Bulten J; Overbeek LI; Berkhof J; Snijders PJ; Meijer CJ
Lancet Oncol; 2014 Mar; 15(3):315-22. PubMed ID: 24529697
[TBL] [Abstract][Full Text] [Related]
51. Do women >or=50 years of age need as much screening as women <50 years after they have had negative screening results?
Armaroli P; Gallo F; Bellomi A; Ciatto S; Consonni D; Davi D; Giorgi-Rossi P; Iossa A; Mancini E; Naldoni C; Polla E; Ronco G; Serafini M; Vergini V; Zanier L; Zappa M; Segnan N
Br J Cancer; 2008 Jul; 99(2):239-44. PubMed ID: 18594534
[TBL] [Abstract][Full Text] [Related]
52. The use of screening episodes linked to CIN3 and invasive cancer registrations to study outcomes from the NHS Cervical Screening Programme.
Blanks RG; Moss SM; Coleman DA; Addou S; Swerdlow AJ
Cytopathology; 2009 Jun; 20(3):154-60. PubMed ID: 19207309
[TBL] [Abstract][Full Text] [Related]
53. A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening.
Cadman L; Wilkes S; Mansour D; Austin J; Ashdown-Barr L; Edwards R; Kleeman M; Szarewski A
J Med Screen; 2015 Mar; 22(1):28-37. PubMed ID: 25403717
[TBL] [Abstract][Full Text] [Related]
54. Indicators for monitoring screening programs with primary HPV test.
Zorzi M; Giorgi Rossi P;
Epidemiol Prev; 2017; 41(1 Suppl 1):1-32. PubMed ID: 28322534
[TBL] [Abstract][Full Text] [Related]
55. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
56. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
58. Quality of colposcopy and treatment: data from the national survey of Italian organised cervical screening programmes. 2008 activity.
Volante R; Giubilato P; Ronco G
Epidemiol Prev; 2010; 34(5-6 Suppl 4):73-80. PubMed ID: 21220838
[TBL] [Abstract][Full Text] [Related]
59. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
[TBL] [Abstract][Full Text] [Related]
60. HPV screening performance indicators in women who previously tested HPV-negative: The second round of Vallecamonica screening programme, Northern Italy.
Pasquale L; Rossi PG; Carozzi F; Domenighini S; Ruggeri C; Cecconami L; Morana C; Chiaramonte M; Chiudinelli D; Piccolomini M; Marchione R; Confortini M
J Med Screen; 2020 Dec; 27(4):207-214. PubMed ID: 32102618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
